Rapid Assay Monitors Influenza Virus Susceptibility
|
By LabMedica International staff writers Posted on 17 May 2017 |
|
Image: The prototype device and kit for the influenza Antiviral Resistance Test (iART) (Photo courtesy of Becton Dickinson).
Early detection of drug-resistant influenza viruses is needed for timely modification of policies and recommendations on the use of antivirals. In many countries, neuraminidase (NA) inhibitor(s) are the medications of choice for treatment and prophylaxis of influenza infections, with oseltamivir being most commonly prescribed.
There have been reports of locally transmitted oseltamivir-resistant A(H1N1)pdm09 viruses harboring the NA amino acid (AA) substitution H275Y, the marker of clinically relevant resistance to oseltamivir. Several genotypic methods including pyrosequencing have been implemented by surveillance laboratories to screen clinical specimens for the presence of H275Y.
Scientists at the Centers for Disease Control and Prevention and their international colleagues used a new rapid assay for detecting oseltamivir resistance in influenza virus, iART, to test 149 clinical specimens. The iART utilizes an advanced enzyme substrate that enables measurement of NA activity in virus isolates and in clinical specimens. Unlike the substrate used in the bioluminescence-based assay, the substrate used in iART is specific to influenza NA, making it more suitable for testing clinical specimens that may contain other pathogens.
The rapid prototype iART assay was developed by Becton Dickinson and the results were obtained for 132 specimens, with iART indicating 41 as “resistant.” For these, sequence analysis found known and suspected markers of oseltamivir resistance, while no such markers were detected for the remaining 91 samples. Viruses isolated from the 41 specimens showed reduced or highly reduced inhibition by neuraminidase inhibition assay.
The authors concluded that their data showed that the iART assay can become a valuable tool for surveillance laboratories. The assay offers a fast mean for detecting viruses displaying reduced inhibition/highly RI (RI/HRI) against oseltamivir in either isolates or clinical specimens. It is a simple approach where signal measurement, data analysis and interpretation are done by a compact portable device. The study was published on May 4, 2017, in the journal Eurosurveillance.
There have been reports of locally transmitted oseltamivir-resistant A(H1N1)pdm09 viruses harboring the NA amino acid (AA) substitution H275Y, the marker of clinically relevant resistance to oseltamivir. Several genotypic methods including pyrosequencing have been implemented by surveillance laboratories to screen clinical specimens for the presence of H275Y.
Scientists at the Centers for Disease Control and Prevention and their international colleagues used a new rapid assay for detecting oseltamivir resistance in influenza virus, iART, to test 149 clinical specimens. The iART utilizes an advanced enzyme substrate that enables measurement of NA activity in virus isolates and in clinical specimens. Unlike the substrate used in the bioluminescence-based assay, the substrate used in iART is specific to influenza NA, making it more suitable for testing clinical specimens that may contain other pathogens.
The rapid prototype iART assay was developed by Becton Dickinson and the results were obtained for 132 specimens, with iART indicating 41 as “resistant.” For these, sequence analysis found known and suspected markers of oseltamivir resistance, while no such markers were detected for the remaining 91 samples. Viruses isolated from the 41 specimens showed reduced or highly reduced inhibition by neuraminidase inhibition assay.
The authors concluded that their data showed that the iART assay can become a valuable tool for surveillance laboratories. The assay offers a fast mean for detecting viruses displaying reduced inhibition/highly RI (RI/HRI) against oseltamivir in either isolates or clinical specimens. It is a simple approach where signal measurement, data analysis and interpretation are done by a compact portable device. The study was published on May 4, 2017, in the journal Eurosurveillance.
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
Latest Microbiology News
- New Blood Test Detects Up to Five Infectious Diseases at POC
- Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read more
Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read more
Hematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more